

## Preventive Care Services - 2022

The Patient Protection and Affordable Care Act (PPACA) and the Health Care and Education Reconciliation Act of 2010 (HCERA) has designated the services listed below as preventive benefits and available with no cost-sharing when provided by an in-network provider. This information is intended as a reference tool for your convenience and is not a guarantee of payment. This guide is subject to change based on new or revised laws and/or regulations, additional guidance and/or medical policy.

\*\*Services are still subject to Medical Management Criteria\*\*

## Wellness Examinations

Preventive Care Services that may be provided during a Wellness Examination:

- |  |  |
|--|--|
| <ul style="list-style-type: none"> <li>▶ Administration/Interpretation of Health Risk</li> <li>▶ Assessment Instrument</li> <li>▶ Anxiety screening</li> <li>▶ Autism screening</li> <li>▶ Blood pressure measurement for high blood pressure screening/Preeclampsia screening</li> <li>▶ Breast-feeding counseling/support</li> <li>▶ Counseling/education to minimize exposure to ultraviolet radiation</li> <li>▶ Counseling to prevent initiation of tobacco use</li> <li>▶ Counseling related to sexual behavior/sexually transmitted infection (STI) prevention including HIV Preexposure Prophylaxis (PrEP) related adherence counseling and pre- and postprescription follow up counseling</li> <li>▶ Critical congenital heart disease screening</li> <li>▶ Depression screening/Maternal Depression screening</li> </ul> | <ul style="list-style-type: none"> <li>▶ Discussion of aspirin prophylaxis</li> <li>▶ Discussion of chemoprevention with women at risk for breast cancer</li> <li>▶ Discussion/referral for genetic counseling/evaluation for BRCA testing</li> <li>▶ Hearing and vision screening</li> <li>▶ Intimate partner/interpersonal and domestic violence screening/referral to support services</li> <li>▶ Obesity screening/counseling regarding weight loss, healthy diet and exercise</li> <li>▶ Oral health assessment/discussion of water fluoridation/referral to dental home</li> <li>▶ Psychosocial/Behavioral assessment</li> <li>▶ Tobacco use screening/counseling</li> <li>▶ Unhealthy Alcohol use and substance abuse screening/counseling</li> <li>▶ Urinary incontinence screening</li> </ul> |
|--|--|

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Abdominal Aortic Aneurysm, Screening</b></p> <p>USPSTF Rating (Dec. 2019): B The USPSTF recommends 1-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men aged 65-75 years who have ever smoked</p>	76706	<p style="color: blue;">Routine diagnosis list</p> <p>F17.210, F17.211, F17.213, F17.218, F17.219, Z87.891</p>	<p>Males age 65 - 75 years One per lifetime</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Anemia Screening in Children</b></p> <p>Bright Futures  Recommends anemia screening for children under the age of 21 years of age which includes hemoglobin and hematocrit screening.</p>	<p>Screening:  85013, 85014, 85018, 85025, 85027, 85041, G0306, G0307</p> <p>Blood Draw:  36415, 36416</p>	<p>Routine diagnosis list</p>	<p>Birth to age 21.  No frequency limit.</p>
<p><b>Aspirin Use Preventive Medication</b></p> <p>USPSTF Rating (April 2016): B  The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.</p> <p>USPSTF Rating (Sept. 2021): B  The USPSTF recommends the use of low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in persons who are at high risk for preeclampsia.</p>			<p>For aspirin prophylaxis, refer to Rx plan</p>
<p><b>Bacteriuria Screening</b></p> <p>USPSTF Rating (Sept. 2019): A  The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons.</p>	<p>81007, 87086, 87088</p>	<p>Pregnancy diagnosis list</p>	<p>Pregnant women</p>
<p><b>Breast Cancer/Ovarian Cancer risk assessment: Genetic counseling for women at risk</b></p> <p>See BRCA1/BRCA2 below for USPSTF rating and recommendation</p>	<p>96040, 99401 - 99404, S0265</p>	<p>Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.43</p>	<p>Females only  Two per lifetime</p>
<p><b>BRCA1/BRCA2 Genetic Testing for susceptibility to breast or ovarian cancer, if indicated: Women</b></p> <p>USPSTF Rating (Aug. 2019): B  The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.</p>	<p>BRCA Lab Screening:  81162 - 81167, 81212, 81215, 81216, 81217</p> <p>Blood Draw:  36415, 36416</p>	<p>Z15.01, Z15.02, Z31.5, Z80.3, Z80.41, Z85.3, Z85.44</p>	<p>These services are subject to Medical Policy and prior authorization may be required</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Breast Cancer Screening</b></p> <p>USPSTF Rating (Jan. 2016): B The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.</p> <p>HRSA Requirement (Dec. 2016): Recommends that average-risk women initiate mammography screening no earlier than age 40 and no later than age 50. Screening mammography should occur at least biennially and as frequently as annually. Screening should continue through at least age 74 and age alone should not be the basis to discontinue screening. These screening recommendations are for women at average risk of breast cancer. Women at increased risk should also undergo periodic mammography screening; however, recommendations for additional services are beyond the scope of this recommendation.</p>	<p>77063, 77065, 77066, 77067</p> <p>Rev code: 0403</p>	<p>Any diagnosis code</p>	<p>One annually for females age 40 and up</p>
<p><b>Breast Cancer Prevention Medication</b></p> <p>USPSTF Rating (Sept. 2019): B The USPSTF recommends that clinicians offer to prescribe risk reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.</p>	<p>Rx only</p>		<p>For breast cancer prevention medication, refer to the Rx plan.</p>
<p><b>Breastfeeding Services and Supplies</b></p> <p>USPSTF Rating (Oct. 2016): B The USPSTF recommends providing interventions during pregnancy and after birth to support breastfeeding.</p> <p>HRSA Requirement (Dec. 2016): Recommends comprehensive lactation support services (including counseling, education, and breastfeeding equipment and supplies) during the antenatal, perinatal, and postpartum periods to ensure the successful initiation and maintenance of breastfeeding.</p>	<p>Counseling and Education: 99401 - 99404, 99411, 99412, S9443</p> <p>Breastfeeding Equipment &amp; Supplies:</p> <p><i>Breast Pumps (Manual &amp; Electric):</i> E0602RR E0603RR, for rental. E0602NU &amp; E0603NU for purchase</p> <p><i>Breast Pump (Hospital grade):</i> E0604RR**</p> <p><i>Breast Pump Supplies:</i> A4281, A4282, A4283, A4284, A4285, A4286</p>	<p>Pregnancy diagnosis list</p>	<p>In conjunction with each birth from a DME supplier</p> <p>**E0604RR, rental only with codes P05.00 - P07.39, P27.0 - P27.9, P29.30, P29.38, P92.1 - P92.9, Q20.0 - Q37.9, Q38.1 - Q38.3, Q90.0-Q91.7, Q93.3-Q93.9, R63.30 - R63.39, Z64.1</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Cervical Cancer Screening (Includes HPV)</b></p> <p>USPSTF Rating (Aug. 2018): A The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21-29 years.</p> <p>For women aged 30 to 65 years, the USPSTF recommends: Screening every 3 years with cervical cytology alone, Every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or Every 5 years with hrHPV testing in combination with cytology (cotesting).</p> <p>Bright Futures, March 2014: Adolescents should no longer be routinely screened for cervical dysplasia until age 21.</p> <p>HRSA Requirement (Dec. 2016): Recommends cervical cancer screening for average-risk women aged 21 to 65 years. For women aged 21 to 29 years recommends cervical cancer screening using cervical cytology (Pap test) every 3 years. Cotesting with cytology and human papillomavirus testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with cytology and human papillomavirus testing every 5 years or cytology alone every 3 years. Women who are at average risk should not be screened more than once every 3 years.</p>	<p>0500T, 87623, 87624, 87625, 88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88155, 88164, 88165, 88166, 88167, 88174, 88175, G0101, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, G0476, P3000, P3001, Q0091</p>	<p>Routine diagnosis list</p>	<p>Females age 21 and up</p>
<p><b>Chlamydia Infection Screening</b></p> <p>USPSTF Rating (Sept. 2014): B The USPSTF recommends screening for chlamydia in sexually active women age 24 years and younger and in older women who are at increased risk for infection.</p> <p>Notes: This recommendation applies to all sexually active adolescents and adult women, including pregnant women.</p> <p>Bright Futures recommends sexually transmitted infection screening be conducted if risk assessment is positive between ages 11-21 years.</p>	<p>Chlamydia Infection Screening: 86631, 86632, 87110, 87205, 87270, 87320, 87490, 87491, 87492, 87800, 87801, 87810</p> <p>Blood Draw: 36415, 36416 Blood draw codes only apply to lab codes 86631 or 86632</p> <p><i>For STI Prevention Counseling see Sexually Transmitted Infection (STI) Prevention Counseling</i></p>	<p>Routine diagnosis list or pregnancy diagnosis list</p>	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Cholesterol Screening (Lipid Disorders Screening): children/adolescents</b></p> <p>Bright Futures (April 2014): Risk Assessment: Recommended at 24 mo, 4 years, 6 years, 8 years, 12 years, 13 years, 14 years, 15 years, 16 years. Screening Lab Work: Conduct if risk assessment is positive, or, at the following intervals: once between age 9-11 years; once between age 17-21 years</p>	<p>Screening Lab Work: 80061, 82465, 83718, 83719, 83721, 83722, 84478</p> <p>Blood Draw: 36415, 36416</p>	<p><a href="#">Routine diagnosis list</a></p>	
<p><b>Cholesterol Screening (Lipid Disorders Screening): Adults</b></p> <p>USPSTF Rating (Nov. 2016): B Statin Use for the Primary Prevention of Cardiovascular Disease in Adults The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (i.e., symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all of the following criteria are met: 1. They are aged 40 to 75 years; 2. They have 1 or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking); and 3. They have a calculated 10-year risk of a cardiovascular event of 10% or greater.</p> <p>Identification of dyslipidemia and calculation of 10-year CVD event risk requires universal lipids screening in adults aged 40 to 75 years.</p> <p>Bright Futures (April 2014): Risk Assessment: Recommended at 24 mo, 4 years, 6 years, 8 years, 12 years, 13 years, 14 years, 15 years, 16 years. Screening Lab Work: Conduct if risk assessment is positive, or, at the following intervals: once between age 9-11 years; once between age 17-21 years</p>	<p>Screening Lab Work: 80061, 82465, 83718, 83719, 83721, 83722, 84478</p> <p>Blood Draw: 36415, 36416</p>	<p><a href="#">Routine diagnosis list</a></p>	<p>Age 2 - 21 years Age 40–75 years annually</p> <p>For statin medications, refer to Rx plan</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Colorectal Cancer Screening</b></p> <p>USPSTF Rating (May 2021): B The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years.</p> <p>USPSTF Rating (May 2021): A The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years.</p>	<p>Fecal occult blood test (FOBT) &amp; Fecal immunochemical test (FIT) G0328, 82270, 82274</p> <p>Sigmoidoscopy G0104, G0106, 45330, 45331, 45333, 45338, 45346</p> <p>Colonoscopy G0105, G0120, G0121, G0122, 44388, 44389, 44392, 44394, 45378, 45380, 45381, 45384, 45385, 45388, 45390, 45391, 45392</p> <p>Computed tomographic (CT) colonography 74263</p> <p>Barium enema (BE) (included in colonoscopy) 74270, 74280</p> <p>Fecal DNA(Cologuard) 81528</p> <p>Pre-Op/Consultation: S0285, 99202 - 99205, 99211 - 99215, 99241 - 99245</p> <p>Pathology: 88304, 88305</p> <p>Anesthesia: 00811, 00812, 99152, 99153, 99156, 99157, G0500</p> <p>Facility Revenue Codes: 360, 490, 750 &amp; 761</p>	<p>Routine diagnosis list</p>	<p>Age 45 - 75 years</p> <ul style="list-style-type: none"> <li>▶ Fecal occult blood testing (FOBT)/fecal immunochemical test (FIT) annually; or</li> <li>▶ Sigmoidoscopy every five years; or</li> <li>▶ Colonoscopy every 10 years; or</li> <li>▶ Computed tomographic colonography (virtual colonoscopy) every five years; or</li> <li>▶ Double contrast barium enema (DCBE) every five years</li> <li>▶ Stool-based deoxyribonucleic acid (DNA) (i.e., Cologuard) every three years</li> </ul> <p>For Bowel Prep Products for Colorectal Cancer Screenings, refer to Rx plan.</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Contraceptive Methods and Counseling</b></p> <p>HRSA Recommendation December 2019</p> <p>The Women's Preventive Services Initiative recommends that adolescent and adult women have access to the full range of female-controlled contraceptives to prevent unintended pregnancy and improve birth outcomes. Contraceptive care should include contraceptive counseling, initiation of contraceptive use, and follow-up care (e.g., management, and evaluation as well as changes to and removal or discontinuation of the contraceptive method). The Women's Preventive Services Initiative recommends that the full range of female-controlled U.S. Food and Drug Administration-approved contraceptive methods, effective family planning practices, and sterilization procedures be available as part of contraceptive care. The full range of contraceptive methods for women currently identified by the U.S. Food and Drug Administration include: (1) sterilization surgery for women, (2) surgical sterilization via implant for women, (3) implantable rods, (4) copper intrauterine devices, (5) intrauterine devices with progestin (all durations and doses), (6) the shot or injection, (7) oral contraceptives (combined pill), (8) oral contraceptives (progestin only, and), (9) oral contraceptives (extended or continuous use), (10) the contraceptive patch, (11) vaginal contraceptive rings, (12) diaphragms, (13) contraceptive sponges, (14) cervical caps, (15) female condoms, (16) spermicides, and (17) emergency contraception (levonorgestrel), and (18) emergency contraception (ulipristal acetate), and additional methods as identified by the FDA. Additionally, instruction in fertility awareness-based methods, including the lactation amenorrhea method, although less effective, should be provided for women desiring an alternative method.</p>	<p>Sterilizations: Tubal Ligation, Oviduct Occlusion: 58565, 58600, 58605, 58611, 58615, 58670, 58671, 58700, 59525, A4264,</p> <p>Tubal Ligation Follow-up (only with diagnosis code Z98.51) Hysterosalpingogram Catheterization and Introduction of Saline or Contrast Material: 58340 Hysterosalpingography: 74740 Contrast Material: Q9967</p> <p>Pathology: 88302</p> <p>Anesthesia for Sterilization: 00851, 00940, 00942, 00950, 00952, 01960, 01961, 01965, 01966, 01967, 01968</p> <p>Services for insertion/removal of intrauterine devices, implants; fitting diaphragm or cervical cap: 11976, 11981, 11982, 11983, 57170, 58300, 58301, A4261, A4266, S4981, S4989,</p> <p>Devices and implants: J7300 - J7307 J7294 - J7298</p> <p>Injections: J1050 (injection) 96372 (administration)</p> <p>E&amp;M codes and 81025: Dr. visits related to contraceptive services and urine pregnancy test</p>	<p><a href="#">Contraceptive diagnosis list</a></p>	<p>For oral /emergency contraception, refer to Rx plan</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Depression in Adults (Screening)</b></p> <p>USPSTF Rating (Jan. 2016): B The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.</p> <p>USPSTF Rating (Feb. 2019): B The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions.</p> <p>HRSA Requirement (Dec. 2019): The Women’s Preventive Services Initiative recommends screening for anxiety in adolescent and adult women, including those who are pregnant or postpartum. Optimal screening intervals are unknown and clinical judgement should be used to determine screening frequency. Given the high prevalence of anxiety disorders, lack of recognition in clinical practices, and multiple problems associated with untreated anxiety, clinicians should consider screening women who have not been recently screened.</p>	<p>96127, 96161, G0444</p> <p>Maternal/Perinatal depression screening: 96156, 96158, 96159, 96160, 96161, 96164, 96165, 96167, 96168</p> <p>**Maternal/Perinatal depression counseling interventions: 99202 - 99205, 99211 - 99215, 99401 - 99404, 99411, 99412, G0463</p>	<p><a href="#">Routine diagnosis list</a></p> <p>Maternal/Perinatal depression screening: <a href="#">Pregnancy diagnosis list</a> or F05, F30.XX, F34.1, F32.9, F53.0 – F53.1, G47.9, R53.81, R53.83, R45</p> <p>**Counseling interventions for maternal/perinatal depression must be billed with either Z13.32 or Z39.2</p>	
<p><b>Depression in Children and Adolescents (Screening)</b></p> <p>USPSTF Rating (Feb. 2016): B The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 -18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.</p> <p>Bright Futures (February 2017): Maternal Depression Screening: Routine screening for postpartum depression should be integrated into well-child visits at 1, 2, 4, and 6 months of age. Note: The Bright Futures Periodicity Schedule recommends depression screening begin at age 12-21 years.</p>	<p>96127, 96161, G0444</p>	<p><a href="#">Routine diagnosis list</a></p>	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Developmental/Behavioral Screening</b></p> <p>Bright Futures:</p> <ul style="list-style-type: none"> <li>▶ A formal, standardized developmental screen is recommended during the 9 month visit.</li> <li>▶ A formal, standardized developmental screen is recommended during the 18 month visit, including a formal autism screen.</li> <li>▶ A formal, standardized autism screen is recommended during the 24 month visit.</li> <li>▶ A formal, standardized developmental screen is recommended during the 30 month visit.</li> </ul>	96110, 96127, G0451, S0302	Routine diagnosis list	Birth to age 3
<p><b>Diabetes (Type 2) Screening</b></p> <p>USPSTF Rating (Aug. 2021): B The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interventions.</p>	<p>Diabetes Screening: 82947, 82948, 82950, 82951, 82952, 83036</p> <p>Blood Draw: 36415, 36416</p> <p><i>For counseling, see Nutrition/Physical Activity Counseling, Behavioral Interventions for Cardiovascular, Obesity, and Pregnancy</i></p> <p><i>For gestational diabetes, see Gestational Diabetes Mellitus Screening</i></p>	Any diagnosis code	
<p><b>Fall Prevention: community dwelling adults age 65 years and older with risk factors</b></p> <p>USPSTF Rating (April 2018): B The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls.</p>	97110, 97112, 97116, 97161, 97162, 97163, 97164, 97530, G0151, G0159	Z91.81	Age 65 and up
<p><b>Fluoride Application (Dental Caries)</b></p> <p>USPSTF Rating (Dec 2021): B Children From Birth Through Age 5 Years. The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.</p> <p>USPSTF Rating (Dec 2021): B The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.</p> <p>Bright Futures (April 2017): For those at high risk, consider application of fluoride varnish for caries prevention every 3 to 6 months between ages 6 months to 5 years.</p>	<p>Fluoride Application: 99188</p> <p>Oral health risk assessment: 96160, 96161</p>	Any diagnosis code	<p>Fluoride application: Birth to age 5</p> <p>Oral health risk assessment: 6 months to 6 years</p> <p>For oral fluoride supplementation, refer to Rx plan</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Gestational Diabetes Mellitus Screening</b></p> <p>USPSTF Rating (Aug. 2021): B The USPSTF recommends screening for gestational diabetes mellitus in asymptomatic pregnant women after 24 weeks of gestation.</p> <p>HRSA Requirement (Dec. 2017) The Women's Preventive Services Initiative recommends women with a history of gestational diabetes mellitus (GDM) who are not currently pregnant and who have not previously been diagnosed with type 2 diabetes mellitus should be screened for diabetes mellitus. Initial testing should ideally occur within the first year postpartum and can be conducted as early as 4-6 weeks postpartum. Women with a negative initial postpartum screening test result should be rescreened at least every 3 years for a minimum of 10 years after pregnancy.</p>	<p>Gestational Diabetes Mellitus Screening: 82947, 82948, 82950, 82951, 82952, 83036</p> <p>Blood Draw: 36415, 36416</p> <p><i>For counseling, see <a href="#">Nutrition/Physical Activity Counseling, Behavioral Interventions for Cardiovascular, Obesity, and Pregnancy</a></i></p>	<p><a href="#">Pregnancy diagnosis list</a></p>	
<p><b>Gonorrhea Screening</b></p> <p>USPSTF Rating (Sept. 2014): B The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.</p> <p>Bright Futures recommends sexually transmitted infection screening be conducted if risk assessment is positive between ages 11-21 years.</p>	<p>87590, 87591, 87592, 87801, 87850</p> <p><i>Gonorrhea, Prophylactic Medication, Newborn No code available - usually administered as an ancillary charge while inpatient at time of delivery</i></p> <p><i>For STI Prevention Counseling see <a href="#">Sexually Transmitted Infection (STI) Prevention Counseling</a></i></p>	<p><a href="#">Routine diagnosis list</a> or <a href="#">Pregnancy diagnosis list</a></p>	
<p><b>Hearing Screening</b></p> <p>Bright Futures (April 2017): Hearing Tests: Recommended at ages: Newborn; between 3-5 days to 2 months; 4 years; 5 years, 6 years; 8 years; 10 years; once between age 11-14 years; once between age 15-17 years; once between age 18-21 years; also recommended for those that have a positive risk assessment.</p>	<p>92550, 92551, 92552, 92553, 92558, 92567, 92568, 92579, 92582, 92583, 92585 92586, 92587, 92588, 92650, 92651, V5008</p>	<p><a href="#">Routine diagnosis list</a></p>	<p>Birth - 10 years: no more than 7 tests 11 years to 21 years: no more than 3 tests</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Hepatitis B Virus Infection Screening</b></p> <p><b>Pregnant Women:</b> USPSTF Rating (July 2019): A The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit.</p> <p><b>Adolescents and Adults at Increased Risk for Infection:</b> USPSTF Rating (Dec. 2020): B The USPSTF recommends screening for hepatitis B virus (HBV) infection in persons at high risk for infection.</p>	<p>Hepatitis B Virus Infection Screening: 86704, 86705, 86706, 87340, 87341, G0499</p> <p>Blood Draw: 36415, 36416</p>	<p>Routine diagnosis list or pregnancy diagnosis list</p>	
<p><b>Hepatitis C Virus Infection Screening</b></p> <p>USPSTF Rating (March 2020): B The USPSTF recommends screening for hepatitis C virus infection in adults aged 18-79 years.</p> <p>Bright Futures (March 2021) Bright Futures recommends screening all individuals ages 18 to 79 years at least once for hepatitis C virus infection (HCV)</p>	<p>Hepatitis C Virus Infection Screening: 86803, 86804, 87522, G0472</p> <p>Blood Draw: 36415, 36416</p>	<p>Any diagnosis code</p>	<p>Adults age 18 - 79 years</p>
<p><b>High Blood Pressure Screening</b></p> <p>USPSTF Rating (April 2021):A The USPSTF recommends screening for hypertension in adults 18 years or older with office blood pressure measurement.</p> <p>The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.</p>	<p>Usually included as part of an office visit.</p> <p>Ambulatory Blood Pressure Measurement: 93784, 93786, 93788 or 93790</p>	<p>R03.0, Z01.30, Z01.31</p>	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>HIV (Human Immunodeficiency Virus) Screening for Adolescents and Adults</b></p> <p>USPSTF Rating (June 2019): A The USPSTF recommends that clinicians screen for HIV infection in: Adolescents and adults aged 15- 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. All pregnant persons, including those who present in labor or at delivery whose HIV status is unknown.</p> <p>Note: Bright Futures recommends HIV screening lab work be conducted once between ages 15-18 years. Also recommended anytime between ages 11-14 years, and 19-21 years when a risk assessment is positive.</p> <p>HRSA Requirement (Dec. 2016): Recommends prevention education and risk assessment for human immunodeficiency virus (HIV) infection in adolescents and women at least annually throughout the lifespan. All women should be tested for HIV at least once during their lifetime. Additional screening should be based on risk, and screening annually or more often may be appropriate for adolescents and women with an increased risk of HIV infection. Screening for HIV is recommended for all pregnant women upon initiation of prenatal care with retesting during pregnancy based on risk factors. Rapid HIV testing is recommended for pregnant women who present in active labor with an undocumented HIV status. Screening during pregnancy enables prevention of vertical transmission.</p>	<p>HIV Counseling: 99401-99402</p> <p>HIV Screening: 86689, 86701, 86702, 86703, 87081, 87389, 87390, 87391, 87806, G0432, G0433, G0435, G0475, S3645</p> <p>Blood Draw: 36415, 36416</p>	<p>Routine diagnosis list or pregnancy diagnosis list</p>	<p>No age limit</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>HIV, Pre-exposure Prophylaxis (PrEP)</b></p> <p>USPSTF Rating (June 2019): A The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition.</p> <p>Note: This includes:</p> <ul style="list-style-type: none"> <li>▶Kidney function testing (creatinine)</li> <li>▶Serologic testing for hepatitis B and C virus</li> <li>▶Testing for other STIs</li> <li>▶Pregnancy testing when appropriate</li> <li>▶Ongoing followup and monitoring including HIV testing every 3 months</li> </ul>	<p>The following services for baseline/follow-up testing and monitoring are included per the CDC PrEP guidelines:</p> <p>Kidney function testing (creatinine): 82565, 82575</p> <p>Hepatitis B testing: <i>For Hepatitis B testing, see <a href="#">Hepatitis B Virus Infection Screening</a></i></p> <p>Hepatitis C testing: <i>For Hepatitis C testing, see <a href="#">Hepatitis C Virus Infection Screening</a></i></p> <p>HIV: <i>For HIV screening and counseling, see <a href="#">HIV (Human Immunodeficiency Virus) Screening for Adolescents and Adults</a></i></p> <p>STI Testing: <i>For Sexually Transmitted Infection (STI) screenings, see <a href="#">Chlamydia Infection Screening, Gonorrhea Screening and Syphilis Screening</a></i></p> <p>Pregnancy testing (when appropriate): 81025, 84702, 84703</p> <p>E/M Office Visits</p>	<p>Z11.3, Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53</p>	<p>For PrEP medications, refer to Rx plan.</p>
<p><b>Lead Screening</b></p> <p>Bright Futures: Screening Lab Work: Conduct risk assessment or screening, as appropriate, at the following intervals: 12 mo and 24 mo. Risk Assessment, and Screening if positive: Recommended at 6 mo, 9mo, 12 mo, 18 mo, 24 mo, 3 years, 4 years, 5 years and 6 years.</p>	<p>Lead Screening: 83655</p> <p>Blood Draw: 36415, 36416</p>	<p><a href="#">Routine diagnosis list</a></p>	<p>Age 6 months - 6 years. No frequency limit.</p>
<p><b>Lung Cancer Screening/Counseling</b></p> <p>USPSTF Rating (March 2021): B The USPSTF recommends annual screening for lung cancer with lowdose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery</p>	<p>Counseling: G0296</p> <p>Screening: 71271</p>	<p>Any diagnosis code</p>	<p>Ages 50 - 80 years annually with history of smoking</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Newborn Screening</b></p> <p>All newborns</p> <p>USPSTF Rating (March 2008): A Hypothyroidism Screening: Screening for congenital hypothyroidism in newborns.</p> <p>USPSTF Rating (March 2008): A Phenylketonuria Screening: Screening for phenylketonuria (PKU) in newborns.</p> <p>USPSTF Rating (Sept. 2007): A Sickle Cell Screening: Screening for sickle cell disease in newborns.</p> <p>Bright Futures Recommends screening for critical congenital heart disease using pulse oximetry for newborns after 24 hours of age, before discharge from the hospital</p>	<p>Bilirubin Screening: 82247, 82248, 88720</p> <p>Congenital Hypothyroidism Screening: 84436, 84437, 84443, 84439, S3620</p> <p>Metabolic Screening Panel: 82017, 82136, 82261, 82759, 82760, 82775, 82776, 83020, 83498, 83516, 83789, 84030, 84437, 84443, 86355 S3620</p> <p>Phenylketonuria Screening: 84030, S3620</p> <p>Sickle Cell Screening: 83020, 83021, 83030, 83033, 83051, 85660 S3850</p> <p>Other: 86359</p> <p>Blood Draw: 36415, 36416</p> <p>Critical Congenital Heart Disease Screening: Included with facility fee</p> <p>Gonorrhea Prophylactic Ocular Medication to Prevent Blindness: See <a href="#">Gonorrhea Screening</a></p>	<p>Any diagnosis code</p>	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Nutrition/Physical Activity Counseling, Behavioral Interventions for Cardiovascular, Obesity, and Pregnancy</b></p> <p>USPSTF Rating (Nov. 2020): B The USPSTF recommends offering or referring adults with cardiovascular disease risk factors to behavioral counseling interventions to promote a healthy diet and physical activity.</p> <p>USPSTF Rating (Sept. 2018): B The USPSTF recommends that clinicians offer or refer adults with a body mass index (BMI) of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive multicomponent behavioral interventions.</p> <p>USPSTF Rating (June 2017): B The USPSTF recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer or refer them to comprehensive, intensive behavioral interventions to promote improvements in weight status.</p> <p>USPSTF Rating (May 2021): B The USPSTF recommends that clinicians offer pregnant persons effective behavioral counseling interventions aimed at promoting healthy weight gain and preventing excess gestational weight gain in pregnancy.</p>	<p>Medical Nutrition Therapy or Counseling: 97802, 97803, 97804, G0270, G0271, S9470</p> <p>Preventive Medicine Individual Counseling: 99401, 99402, 99403, 99404</p> <p>Behavioral Counseling or Therapy: G0446, G0447, G0473</p>	<p>Any diagnosis code</p>	
<p><b>Osteoporosis Screening</b></p> <p>USPSTF Rating (June 2018): B Women 65 and older: The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.</p> <p>USPSTF Rating (June 2018): B Postmenopausal women younger than 65 years at increased risk of osteoporosis: The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.</p>	<p>76977, 77078, 77080, 77081, G0130</p>	<p><a href="#">Routine diagnosis list</a></p>	<p>Females only</p>
<p><b>Prenatal Care</b></p> <p>USPSTF Rating (April 2017): B The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.</p>	<p>Prenatal Office Visits: Evaluation and Management (Office Visits): 59425, 59426, 99202 - 99215, 99417, G0463</p>	<p><a href="#">Pregnancy diagnosis list</a></p>	<p>Females only</p> <p>For folic acid supplements, refer to Rx plan</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Rh incompatibility Screening</b></p> <p>USPSTF Rating (Feb. 2004): A Rh (D) blood typing and antibody testing for all pregnant women during their first visit for pregnancyrelated care.</p> <p>USPSTF Rating (Feb. 2004): B Repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks' gestation, unless the biological father is known to be Rh (D)-negative</p>	<p>86900, 86901, 80055, 80081, 86850</p>	<p><a href="#">Pregnancy diagnosis list</a></p>	<p>Females only</p>
<p><b>Sexually Transmitted Infection (STI) Prevention Counseling</b></p> <p>USPSTF Rating (Aug. 2020): B The USPSTF recommends behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs).</p> <p>HRSA Requirement (Dec. 2016): Recommends directed behavioral counseling by a health care provider or other appropriately trained individual for sexually active adolescent and adult women at an increased risk for STIs. This recommendation further recommends that health care providers use a woman's sexual history and risk factors to help identify those at an increased risk of STIs. Risk factors may include age younger than 25, a recent history of an STI, a new sex partner, multiple partners, a partner with concurrent partners, a partner with an STI, and a lack of or inconsistent condom use. For adolescents and women not identified as high risk, counseling to reduce the risk of STIs should be considered, as determined by clinical judgement.</p>	<p>STIs Behavioral Counseling: G0445</p> <p>Preventive Medicine Individual Counseling 99401, 99402, 99403, 99404, 99411, 99412</p> <p><i>Note: For Sexually Transmitted Infection (STI) screenings, see <a href="#">Chlamydia Infection Screening</a>, <a href="#">Gonorrhea Screening</a> and <a href="#">Syphilis Screening</a></i></p>	<p>Any diagnosis code</p>	<p>G0445 is limited to twice per year</p>
<p><b>Skin Cancer</b></p> <p>USPSTF Rating (March 2018): B The USPSTF recommends counseling young adults, adolescents, children and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons ages 6 months to 24 years with fair skin types to reduce their risk of skin cancer.</p>			<p>This service is included in a preventive care wellness examination or focused E&amp;M visit.</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Smoking and Tobacco Cessation Counseling/Interventions</b></p> <p>USPSTF Rating (Jan. 2021): A Pregnant Persons (A): The USPSTF recommends that clinicians ask all pregnant persons about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant persons who use tobacco.</p> <p>Nonpregnant Adults (A):The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and US Food and Drug Administration (FDA)–approved pharmacotherapy for cessation to nonpregnant adults who use tobacco.</p> <p>USPSTF Rating (April 2013): B The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.</p> <p>Bright Futures (April 2017): Bright Futures recommends tobacco use assessments from age 11-21 years.</p>	<p>99406, 99407</p>	<p>Any diagnosis code</p>	<p>For smoking cessation medications, refer to Rx plan</p>
<p><b>Syphilis Screening</b></p> <p>Non-Pregnant Adults and Adolescents at Increased Risk: USPSTF Rating (June 2016): A The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection (asymptomatic, nonpregnant adults and adolescents who are at increased risk for syphilis infection).</p> <p>Pregnant Women: USPSTF Rating (Sept. 2018): A The USPSTF recommends early screening for syphilis infection in all pregnant women.</p> <p>Bright Futures recommends sexually transmitted infection screening be conducted if risk assessment is positive between ages 11-21 years.</p>	<p>Syphilis Screening: 86592, 86593, 86780</p> <p>Blood Draw: 36415, 36416</p> <p><i>For STI Prevention Counseling see <a href="#">Sexually Transmitted Infection (STI) Prevention Counseling</a></i></p>	<p><a href="#">Routine diagnosis list or pregnancy diagnosis list</a></p>	

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Tuberculosis Screening</b></p> <p>USPSTF Rating (Sept. 2016): B The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.</p> <p>This recommendation applies to asymptomatic adults 18 years and older at increased risk for tuberculosis.</p>	<p>Screening: 86480, 86481, 86580</p> <p>Blood Draw: 36415, 36416</p> <p>Follow-up Visit to Check Results: 99211</p>	<p>R76.11, R76.12, Z20.1, Z00.121, Z00.129, Z11.1, Z11.7, Z20.1, Z22.7, Z86.15</p>	<p>No age limit</p>
<p><b>Unhealthy Alcohol and Drug Use</b></p> <p>USPSTF Rating (Nov. 2018): B The USPSTF recommends screening for unhealthy alcohol use in primary care settings in adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.</p> <p>USPSTF Rating (June 2020): B The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.)</p> <p>Bright Futures (April 2017): Bright Futures recommends alcohol or drug use assessments from age 11-21 years.</p>	<p>Alcohol or Drug Use Screening: 99408, 99409, G0442, H0001</p> <p>Counseling: G0396, G0397, G0443, G2011</p>	<p>Any diagnosis code</p>	<p>Age 11 and up</p>

Preventive Service	Procedure Code(s)	Diagnosis Code(s)	Limitations
<p><b>Vision Screening</b></p> <p>USPSTF Rating (Sept. 2017): B The USPSTF recommends vision screening at least once in all children age 3 to 5 years to detect amblyopia or its risk factors.</p> <p>Bright Futures: Visual acuity screening is recommended for age 4 and 5 years as well as in cooperative 3 year olds.</p> <p>Instrument-based screening recommended for age 12 and 24 months, in addition to the well visits at 3-5 years of age.</p> <p>Bright Futures Visits Newborn, First Week; 1, 2, 4, 6, 9, 12, 15, 18 Month; 2, 2½, 7, 9, 11, 13, 14, 16, 17, 18 Through 21 Year</p>	99172, 99173, 99174, 99177	Any diagnosis code	Birth to age 21
<p><b>Wellness Examinations</b></p> <p>Preventive medicine comprehensive evaluation and management services for well-baby, well-child and well-adult, including well-woman include:</p> <ul style="list-style-type: none"> <li>▶ An age-and gender-appropriate history</li> <li>▶ Physical examination</li> <li>▶ Counseling/anticipatory guidance</li> <li>▶ Risk factor reduction interventions</li> <li>▶ The ordering of appropriate immunization(s) and laboratory/screening procedures</li> </ul>	<p>Annual Wellness examinations: 99385 - 99387, 99395 - 99397, G0438, G0439, G0513, G0514</p> <p>Well-woman examinations: 99383 - 99387, 99393 - 99397, G0101, G0438, G0439, S0610 - S0613</p> <p>Natural Family Planning (includes preconception) 99202 - 99205, 99211 - 99215, 99401 - 99404</p> <p>Well-baby/Well-child examinations: 99381 - 99384, 99391 - 99394</p> <p>Inpatient newborn care (physician services only): 99221-99223, 99231 - 99233, 99234 - 99236, 99238, 99239, 99460 - 99464, 99478 - 99480</p>	<p>Routine diagnosis list</p> <p>Routine diagnosis list</p> <p>Natural Family Planning: Z30.02, Z31.61, Z31.69</p> <p>Routine diagnosis list</p>	<p>Each Plan Year, a participant may choose a maximum of two of the following three services:</p> <p>One annual examination with a primary care provider,</p> <p>One annual well-woman examination (Females only beginning at age 10)</p> <p>One natural family planning examination (Females only)</p> <p>If a participant receives one or two of the foregoing services in a calendar year, the services will be covered as provided in the Plan. If a participant receives all three services in a Plan Year, only the first two services the participant receives will be covered as a preventive benefit.</p>

# Immunizations

Immunization	Procedure Code(s)
COVID-19 Vaccine	See Covid-19 Document
Diphtheria, Tetanus, and Acellular Pertussis (DT/DTap) Vaccine	90696, 90697, 90698, 90700, 90702, 90723
Hepatitis A (HepA) Vaccine	90632, 90633, 90634, 90636
Hepatitis B (HepB) Vaccine	90739, 90740, 90743, 90744, 90746, 90747, 90748
Haemophilus Influenzae Type B (Hib) Vaccine	90647, 90648
Human Papillomavirus (HPV) Vaccine	90649, 90650, 90651
Influenza (IIV, LAIV4, RIV4) Vaccine	90630, 90653, 90654, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90664, 90666, 90667, 90668, 90672, 90673, 90674, 90682, 90685, 90686, 90687, 90688, 90689, 90694, 90756, Q2034, Q2035, Q2036, Q2037, Q2038, Q2039
Measles, Mumps, Rubella (MMR) and Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine	90707, 90710
Meningococcal(MenACWY, MenB) Vaccine	90619, 90620, 90621, 90644, 90733, 90734
Pneumococcal (PCV13, PPSV23) Vaccine	90732, 90670, 90677
Polio (IPV) Vaccine	90713
Rotavirus (RV) Vaccine	90680, 90681
Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Tdap/Td)	90714, 90715
Varicella (VAR) Vaccine	90716
Zoster (RZV) Vaccine	90736, 90750
Immunization Administration	90460, 90461, 90471, 90472, 90473, 90474, G0008, G0009, G0010, Rev code 0771

Routine Diagnosis List	
ICD-10 Code(s)	Description
Z00.00	Encounter for general adult medical examination without abnormal findings
Z00.01	Encounter for general adult medical examination with abnormal findings
Z00.110	Health examination for newborn under 8 days old
Z00.111	Health examination for newborn 8 to 28 days old
Z00.121	Encounter for routine child health examination with abnormal findings
Z00.129	Encounter for routine child health examination without abnormal findings
Z00.3	Encounter for examination for adolescent development state
Z00.8	Encounter for other general examination
Z01.00	Encounter for examination of eyes and vision without abnormal findings

Z01.01	Encounter for examination of eyes and vision with abnormal findings
Z01.02	Encounter for examination of eyes and vision following failed vision screening
Z01.020	Encounter for examination of eyes and vision following failed vision screening without abnormal findings
Z01.021	Encounter for examination of eyes and vision following failed vision screening with abnormal findings
Z01.10	Encounter for examination of ears and hearing without abnormal findings
Z01.110	Encounter for hearing examination following failed hearing screening
Z01.118	Encounter for examination of ears and hearing with other abnormal findings
Z01.30	Encounter for examination of blood pressure without abnormal findings
Z01.31	Encounter for examination of blood pressure with abnormal findings
Z01.411	Encounter for gynecological examination (general) (routine) with abnormal findings
Z01.419	Encounter for gynecological examination (general) (routine) without abnormal findings
Z01.42	Encounter for cervical smear to confirm findings of recent normal smear following initial abnormal smear
Z02.83	Encounter for blood-alcohol and blood-drug test
Z11.0	Encounter for screening for intestinal infectious diseases
Z11.1	Encounter for screening for respiratory tuberculosis
Z11.2	Encounter for screening for other bacterial diseases (SYPHILIS)
Z11.3	Encounter for screening for infections with a predominantly sexual mode of transmission
Z11.4	Encounter for screening for human immunodeficiency virus [HIV]
Z11.51	Encounter for screening for human papillomavirus (HPV)
Z11.59	Encounter for screening for other viral diseases
Z11.6	Encounter for screening for other protozoal diseases and helminthiases
Z11.7	Encounter for testing for latent tuberculosis infection
Z11.8	Encounter for screening for other infectious and parasitic diseases
Z11.9	Encounter for screening for infectious and parasitic diseases, unspecified (GONORRHEA)
Z12.2	Encounter for screening for malignant neoplasm of respiratory organs
Z12.10	Encounter for screening for malignant neoplasm of intestinal tract, unspecified
Z12.11	Encounter for screening for malignant neoplasm of colon
Z12.12	Encounter for screening for malignant neoplasm of rectum
Z12.13	Encounter for screening for malignant neoplasm of small intestine
Z12.2	Encounter for screening for malignant neoplasm of respiratory organs
Z12.31	Encounter for screening mammogram for malignant neoplasm of breast
Z12.39	Encounter for other screening for malignant neoplasm of breast
Z12.4	Encounter for screening for malignant neoplasm of cervix
Z12.5	Encounter for screening for malignant neoplasm of prostate
Z12.72	Encounter for screening for malignant neoplasm of vagina

Z12.81	Encounter for screening for malignant neoplasm of oral cavity
Z13.0	Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Z13.1	Encounter for screening for diabetes mellitus
Z13.21	Encounter for screening for nutritional disorder
Z13.22	Encounter for screening for metabolic disorder
Z13.220	Encounter for screening for lipid disorders
Z13.228	Encounter for screening for other metabolic disorders
Z13.29	Encounter for screening for other suspected endocrine disorder
Z13.31	Encounter for screening for depression
Z13.32	Encounter for screening for maternal depression
Z13.39	Encounter for screening examination for other mental health and behavioral disorders
Z13.40	Encounter for screening for unspecified developmental delays
Z13.41	Encounter for autism screening
Z13.42	Encounter for screening for global developmental delays (milestones)
Z13.49	Encounter for screening for other developmental delays
Z13.5	Encounter for screening for eye and ear disorders
Z13.6	Encounter for screening for cardiovascular disorders
Z13.820	Encounter for screening for osteoporosis
Z13.84	Encounter for screening for dental disorders
Z13.88	Encounter for screening for disorder due to exposure to contaminants
Z13.89	Encounter for screening for other disorder
Z15.01	Genetic susceptibility to malignant neoplasm of breast
Z15.02	Genetic susceptibility to malignant neoplasm of ovary
Z20.1	Contact with and (suspected) exposure to tuberculosis
Z20.2	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission
Z20.5	Contact with and (suspected) exposure to viral hepatitis
Z20.6	Contact with and (suspected) exposure to human immunodeficiency virus [HIV]
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status
Z22.7	Latent tuberculosis
Z23	Encounter for immunization
Z29.3	Encounter for prophylactic fluoride administration
Z31.5	Encounter for procreative genetic counseling
Z57.8	Occupational exposure to other risk factors
Z63.6	Dependent relative needing care at home
Z63.79	Other stressful life events affecting family and household

Z65.1	Imprisonment and other incarceration
Z68.25 - Z68.45	BMI 25+
Z69.010 - Z69.12	Encounter for mental health services for abuse
Z69.81	Encounter for mental health services for victim of other abuse
Z69.82	Encounter for mental health services for perpetrator of other abuse
Z71.3	Dietary counseling and surveillance
Z71.41	Alcohol abuse counseling and surveillance of alcoholic
Z71.42	Counseling for family member of alcoholic
Z71.51	Drug abuse counseling and surveillance of drug abuser
Z71.52	Counseling for family member of drug abuser
Z71.53	High risk bisexual behavior
Z71.6	Tobacco abuse counseling
Z71.7	Human immunodeficiency virus [HIV] counseling
Z71.82	Exercise counseling
Z71.83	Encounter for non-procreative genetic counseling
Z71.89	Other specified counseling
Z71.9	Counseling, unspecified
Z72.0	Tobacco use
Z72.51	High risk heterosexual behavior [effective 9/17/2021]
Z72.52	High risk homosexual behavior [effective 9/17/2021]
Z72.53	High risk bisexual behavior [effective 9/17/2021]
Z72.89	Other problems related to lifestyle
Z72.9	Problem related to lifestyle, unspecified
Z73.9	Problem related to life management difficulty, unspecified
Z76.1	Encounter for health supervision and care of foundling
Z76.2	Encounter for health supervision and care of other healthy infant and child
Z76.81	Expectant parent(s) prebirth pediatrician visit
Z76.89	Persons encountering health services in other specified circumstances
Z77.011	Contact with and (suspected) exposure to lead
Z80.0	Family history of malignant neoplasm of digestive organs
Z80.3	Family history of malignant neoplasm of breast
Z80.41	Family history of malignant neoplasm of ovary
Z80.42	Family history of malignant neoplasm of prostate
Z82.49	Family history of ischemic heart disease and other diseases of the circulatory system
Z82.62	Family history of osteoporosis

Z83.3	Family history of diabetes mellitus
Z83.42	Family history of familial hypercholesterolemia
Z83.71	Family history of colonic polyps
Z83.79	Family history of other diseases of the digestive system
Z85.3	Personal history of malignant neoplasm of breast
Z85.43	Personal history of malignant neoplasm of ovary
Z86.010	Personal history of colonic polyps
Z86.15	Personal history of latent tuberculosis infection
Z86.32	Personal history of gestational diabetes
Z86.39	Personal history of other endocrine, nutritional and metabolic disease
Z87.312	Personal history of (healed) stress fracture
Z87.81	Personal history of (healed) traumatic fracture
Z87.891	Personal history of nicotine dependence
Z90.79	Acquired absence of other genital organ(s)
Z91.81	History of falling
Z92.241	Personal history of systemic steroid therapy

<b>Pregnancy Diagnosis List</b>	
<b>ICD-10 Code(s)</b>	<b>Description</b>
O00.00 - O94.53	Pregnancy, Childbirth and the puerperium
P05.00 - P07.39	Disorders of newborn related to length of gestation and fetal growth
P27.0 - P27.9	Respiratory and cardiovascular disorders specific to the perinatal period
P92.1 - P92.9	Respiratory and cardiovascular disorders specific to the perinatal period
Z03.71	Encounter for suspected problem with amniotic cavity and membrane ruled out
Z03.72	Encounter for suspected placental problem ruled out
Z03.73	Encounter for suspected fetal anomaly ruled out
Z03.74	Encounter for suspected problem with fetal growth ruled out
Z03.75	Encounter for suspected cervical shortening ruled out
Z03.79	Encounter for other suspected maternal and fetal conditions ruled out
Z29.13	Encounter for prophylactic Rho(D) immune globulin
Z32.01	Encounter for pregnancy test, result positive
Z32.2	Encounter for childbirth instruction
Z33.1	Pregnant state, incidental
Z33.3	Pregnant state, gestational carrier

Z34.00	Encounter for supervision of normal first pregnancy, unspecified trimester
Z34.01	Encounter for supervision of normal first pregnancy, first trimester
Z34.02	Encounter for supervision of normal first pregnancy, second trimester
Z34.03	Encounter for supervision of normal first pregnancy, third trimester
Z34.80	Encounter for supervision of other normal pregnancy, unspecified trimester
Z34.81	Encounter for supervision of other normal pregnancy, first trimester
Z34.82	Encounter for supervision of other normal pregnancy, second trimester
Z34.83	Encounter for supervision of other normal pregnancy, third trimester
Z34.90	Encounter for supervision of normal pregnancy, unspecified, unspecified trimester
Z34.91	Encounter for supervision of normal pregnancy, unspecified, first trimester
Z34.92	Encounter for supervision of normal pregnancy, unspecified, second trimester
Z34.93	Encounter for supervision of normal pregnancy, unspecified, third trimester
Z36.0	Encounter for antenatal screening for chromosomal anomalies
Z36.1	Encounter for antenatal screening for raised alphafetoprotein level
Z36.2	Encounter for other antenatal screening follow-up
Z36.3	Encounter for antenatal screening for malformations
Z36.4	Encounter for antenatal screening for fetal growth retardation
Z36.5	Encounter for antenatal screening for isoimmunization
Z36.81	Encounter for antenatal screening for hydrops fetalis
Z36.82	Encounter for antenatal screening for nuchal translucency
Z36.83	Encounter for fetal screening for congenital cardiac abnormalities
Z36.84	Encounter for antenatal screening for fetal lung maturity
Z36.85	Encounter for antenatal screening for Streptococcus B
Z36.86	Encounter for antenatal screening for cervical length
Z36.87	Encounter for antenatal screening for uncertain dates
Z36.88	Encounter for antenatal screening for fetal macrosomia
Z36.89	Encounter for other specified antenatal screening
Z36.8A	Encounter for antenatal screening for other genetic defects
Z36.9	Encounter for antenatal screening, unspecified
Z39.1	Encounter for care and examination of lactating mother
Z39.2	Encounter for routine postpartum follow-up
Z3A.00	Weeks of gestation of pregnancy not specified
Z3A.01	Less than 8 weeks gestation of pregnancy
Z3A.08	8 weeks gestation of pregnancy
Z3A.09	9 weeks gestation of pregnancy

Z3A.10	10 weeks gestation of pregnancy
Z3A.11	11 weeks gestation of pregnancy
Z3A.12	12 weeks gestation of pregnancy
Z3A.13	13 weeks gestation of pregnancy
Z3A.14	14 weeks gestation of pregnancy
Z3A.15	15 weeks gestation of pregnancy
Z3A.16	16 weeks gestation of pregnancy
Z3A.17	17 weeks gestation of pregnancy
Z3A.18	18 weeks gestation of pregnancy
Z3A.19	19 weeks gestation of pregnancy
Z3A.20	20 weeks gestation of pregnancy
Z3A.21	21 weeks gestation of pregnancy
Z3A.22	22 weeks gestation of pregnancy
Z3A.23	23 weeks gestation of pregnancy
Z3A.24	24 weeks gestation of pregnancy
Z3A.25	25 weeks gestation of pregnancy
Z3A.26	26 weeks gestation of pregnancy
Z3A.27	27 weeks gestation of pregnancy
Z3A.28	28 weeks gestation of pregnancy
Z3A.29	29 weeks gestation of pregnancy
Z3A.30	30 weeks gestation of pregnancy
Z3A.31	31 weeks gestation of pregnancy
Z3A.32	32 weeks gestation of pregnancy
Z3A.33	33 weeks gestation of pregnancy
Z3A.34	34 weeks gestation of pregnancy
Z3A.35	35 weeks gestation of pregnancy
Z3A.36	36 weeks gestation of pregnancy
Z3A.37	37 weeks gestation of pregnancy
Z3A.38	38 weeks gestation of pregnancy
Z3A.39	39 weeks gestation of pregnancy
Z3A.40	40 weeks gestation of pregnancy
Z3A.41	41 weeks gestation of pregnancy
Z3A.42	42 weeks gestation of pregnancy
Z3A.49	Greater than 42 weeks gestation of pregnancy
Z64.1	Problems related to multiparity

**Contraceptive Diagnosis List**

<b>ICD-10 Code(s)</b>	<b>Description</b>
Z30.011	Encounter for initial prescription of contraceptive pills
Z30.012	Encounter for prescription of emergency contraception
Z30.013	Encounter for initial prescription of injectable contraceptive
Z30.014	Encounter for initial prescription of intrauterine contraceptive device
Z30.015	Encounter for initial prescription of vaginal ring hormonal contraceptive
Z30.016	Encounter for initial prescription of transdermal patch hormonal contraceptive device
Z30.017	Encounter for initial prescription of implantable subdermal contraceptive
Z30.018	Encounter for initial prescription of other contraceptives
Z30.019	Encounter for initial prescription of contraceptives, unspecified
Z30.09	Encounter for other general counseling and advice on contraception
Z30.2	Encounter for sterilization
Z30.40	Encounter for surveillance of contraceptives, unspecified
Z30.41	Encounter for surveillance of contraceptive pills
Z30.42	Encounter for surveillance of injectable contraceptive
Z30.430	Encounter for insertion of intrauterine contraceptive device
Z30.431	Encounter for routine checking of intrauterine contraceptive device
Z30.432	Encounter for removal of intrauterine contraceptive device
Z30.433	Encounter for removal and reinsertion of intrauterine contraceptive device
Z30.44	Encounter for surveillance of vaginal ring hormonal contraceptive device
Z30.45	Encounter for surveillance of transdermal patch hormonal contraceptive device
Z30.46	Encounter for surveillance of implantable subdermal contraceptive
Z30.49	Encounter for surveillance of other contraceptives
Z30.8	Encounter for other contraceptive management
Z30.9	Encounter for contraceptive management, unspecified